In fact, Matt Plocki re-joins the Validair team and brings huge experience to the company’s customers from previous roles in particle monitoring engineering development and hospital pharmaceutical manufacturing – as well as a former technical role at VMSL.
Validair Monitoring Solutions Ltd supplies environmental monitoring (EM) and contamination control solutions from TSI Inc. and ViGIE to customers across the UK and Ireland. While Matt Plocki is based at VMSL’s headquarters in Malvern, Worcestershire, he will support the firm’s customers in all territories with his specialist facility monitoring and particle counter instrumentation knowledge.
Plocki began his journey in the contamination control sector with TSI Inc. where he served as a service technician, dealing with various test & measurement instruments and associated calibration systems, and subsequently joined Validair Monitoring Solutions Ltd as a Technical Support & Development Engineer. After a five-year tenure at VMSL, he moved into a specialist engineering post in pharmaceutical production with Guy’s Hospital, London.
“Now that Matt has returned to Validair from a key role in pharma manufacturing with invaluable first-hand experience of facility monitoring systems, he will be a great asset to our team. His expertise will see him advise and support Validair customers who are considering, implementing or using our FMS solutions. We are delighted to welcome him back,” says Deborah Haisman, Commercial Director at Validair Monitoring Solutions Ltd.
From his time with TSI and more recently in pharmaceutical production at Guy’s Hospital, Plocki also brings applications experience of the TSI BioTrak Real-Time Viable Particle Counter – a microbial EM system that is unique in the global market and that has come into its own with the recent publication of the EU GMP Annex 1 update, which mandates continuous monitoring and the creation of Contamination Control Systems (CCS) to which the BioTrak is ideally suited.
“The BioTrak is not only topical but hugely relevant in the pharma sector thanks to the revised Annex 1,” explains Haisman. “Matt’s experience with this game-changing real-time EM solution is another avenue of practical expertise that we can immediately put at the disposal of our customers and other pharma professionals looking for the optimum non-inferior ARMM solution to meet Annex 1
challenges.”
